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ABSTRACT 
Hepatocellular carcinoma (HCC) is a malignant tumour of the hepatocyte. It is a common malignancy worldwide 
and causes almost half a million deaths annually. Asia is a high risk area. Although surgery (hepatectomy or liver 
transplantation) is the main form of curative treatment, the majority of patients are not eligible for surgery due to extent 
of tumour and dysfunction of liver. Radiopharmaceuticals used for transarterial treatment of HCC were Yttrium 90 
microspheres,  Iodine 131  lipiodol,  Rhenium 188  lipiodol,  and  Holmium 166  Chitosan  complex.  Yittrium 90 
microspheres are glass or resin microspheres of mean sphere diameter of 20 to 30 micrometre. The activity administered 
was about 4 GBq. Reported response rate was about 20%, and median survival was 54 weeks. On inoperable tumours, 
reported objective response of I 131 lipiodol was 40 to 70%, and median survival was six to nine months. It showed 
efficacy similar to TACE. In adjuvant treatment following curative resection of HCC, reported three year survival was 
86% compared with 46% for the control group. The administered activity in both adjuvant and inoperable HCC was 
about  2  GBq  (55  mCi).  Rhenium 188  lipiodol  is  a  new  radioconjugate,  and  using  it  we  treated  70  patients  with 
inoperable HCC. This treatment was a part of a multi centre trial sponsored by the International Atomic Energy Agency. 
Partial response was obtained in 17% of cases, while 49% had stable disease at three months, and 34% showed disease 
progression. In terms of survival, 19% survived one year, 60% for six months, and 90% for three months. The mean 
activity was about 4.6 GBq (124 mCi). This method was safe and free from adverse effects. © 2006 Biomedical Imaging 
and Intervention Journal. All rights reserved. 
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INTRODUCTION 
Hepatocellular  carcinoma  (HCC)  is  a  common 
malignancy worldwide. It is a major cause of death from 
cancer  in  East  Asia,  especially  China,  Japan,  Korea, 
Taiwan, and Singapore. Sub Saharan Africa, particularly 
Zimbabwe,  Ethiopia,  and  Mozambique  faces  a  similar 
problem [1]. 
Surgical resection is generally accepted as the first 
choice  treatment  for  HCC.  Only  about  20%  of  all 
patients,  however,  have  resectable  HCC  at  initial 
presentation, due to its multi focal nature and frequent 
association  with  cirrhosis  [2].  Treatment  of  inoperable 
HCC is mainly palliative. Many non surgical treatment 
modalities  have  been  developed  and  used  for  the 
treatment of HCC. These include percutaneous ethanol 
injection  (PEI),  cryotherapy,  radiofrequency  ablation 
(RFA),  systemic  chemotherapy,  transarterial 
chemoembolisation  (TACE),  hormonal  therapy, 
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immunotherapy, external radiotherapy, and radionuclide 
therapy.  
PEI and RFA techniques have shown some success 
in  the  treatment  of  small  HCCs  [4 6].  The  use  of 
cryotherapy, systemic chemotherapy, hormonal therapy, 
immunotherapy, and external beam radiotherapy for the 
treatment of HCC are either ineffective or have met with 
limited success [7 9]. Hepatic arterial blood flow can be 
obstructed  by  the  injection  of  gelfoam  or  by  placing 
metallic coils. Flow obstruction can be combined  with 
injection  of  a  mixture  of  lipiodol  and  chemotherapy 
drugs, also known as TACE. TACE is widely used for 
the treatment of HCC [10], with the caveat that results 
are better in well selected patients [11]. A randomised 
study by Raoul and co workers has shown a markedly 
better tolerance for I 131 lipiodol than for TACE with 
equal long term outcome [12]. Radionuclide therapy has 
been utilised for palliative treatment of inoperable HCC 
and for adjuvant therapy following curative resection of 
HCC. 
PALLIATIVE RADIONUCLIDE THERAPY FOR INOPERABLE 
HCC 
The radionuclide is usually delivered via the hepatic 
intra arterial  approach.  Iodine 131  (I 131)  lipiodol, 
Yttrium 90 (Y 90) microspheres, and Rhenium 188 (Re 
188) lipiodol are some of the radiopharmaceuticals that 
have  been  utilised.  Monoclonal  antibodies,  such  as, 
anticarcinoembryonic  antigen  and  antiferritin  labelled 
with  Y 90  and  I 131  have  also  been  utilised  and  are 
usually  given  parenterally.  Other  approaches,  such  as, 
ultrasound guided  percutaneous  intra tumoral  injection 
of Y 90  microspheres  have  been used. Tian et al [13] 
treated 27 patients with HCC and six patients with liver 
metastases  using  this  approach,  and  they  found 
encouraging results. In their study, most of the patients 
failed other treatment modalities. Twenty seven patients 
were  still  alive  12  to  32  months  after  treatment,  with 
90.6% of the tumour foci becoming smaller. The serum 
α fetoprotein (AFP) levels were normalised in 10 out of 
13 patients. Doses in the range of 282 Gy to 757 Gy were 
delivered to the tumours. 
I 131 LIPIODOL 
I 131 emits both β and γ rays. The average energy of 
the β rays emitted by I 131 is 181 keV and that of γ rays 
is 364 keV. It is, therefore, suitable for both therapeutic 
and imaging purposes. The physical half life of I 131 is 
8.05 days. Lipiodol is an iodised ethyl ester of the fatty 
acids  of  poppy  seed  oil  containing  38%  of  iodine  by 
weight.  It  is  known  to  selectively  localise  in  HCC 
following intra arterial hepatic administration.  
Many studies have reported encouraging results with 
the use of I 131 lipiodol for the treatment of unresectable 
HCC [14 17]. The activity of I 131 lipiodol administered 
ranges from 740 MBq to 6,220 MBq, either in single or 
multiple  treatments.  Where  the  hepatic  tumours  were 
large, fractionated doses of I 131 lipiodol were given at 
four day intervals [14]. Repeat treatment can be given at 
intervals of 8 to 12 weeks. The objective response rates, 
in  terms  of  radiological  regression  of  tumour  and/or 
reduction in serum α fetoprotein levels, range from 40% 
to 70% [12,14]. Overall, the response of HCC to intra 
arterial I 131 lipiodol appears to be dependent on the size 
of the tumour and the magnitude of the treatment dose 
delivered transarterially. The response was poorer with 
increasing  size  of  tumour  and  lower  administered 
treatment  dose.  This  is  to  be  expected  from  basic 
radiation dosimetry principles, which relate cell death to 
radiation dose absorbed by a tumour.  
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The efficacy of hepatic intra arterial I 131 lipiodol 
for the treatment of HCC is comparable to TACE. I 131 
lipiodol appears to be better tolerated than TACE, with 
fewer  side  effects  experienced  by  the  patients. 
Radionuclide  therapy  is,  therefore,  a  reasonable 
alternative  to  TACE  for  the  treatment  of  unresectable 
HCCs.  Two  studies  have  compared  the  efficacy  of 
hepatic intra arterial I 131 lipiodol therapy with TACE. 
In  the  study  by  Bhattacharya  et  al,  69  patients  with 
unresectable  HCC  received  hepatic  intra arterial 
epirubicin lipiodol  emulsion  and  26  patients  received 
hepatic  intra arterial  I 131  lipiodol  [16].  The  survival 
benefit  at  6  and  12  months  for  either  modality  was 
comparable.  The  actuarial  survival  at  6,  12,  and  24 
months  was  40%,  25%,  and  6%,  respectively,  with 
epirubicin lipiodol, and 58%, 25%, and 0%, respectively, 
with  I 131  lipiodol.  Both  groups  showed  acceptable 
toxicity, such as, mild nausea, fever, and abdominal pain. 
In  a  French  prospective  randomised  trial  [12],  142 
patients were randomised to receive either intra arterial 
injection  of  I 131  lipiodol  (73  patients)  or 
chemoembolisation  (69  patients).  It  was  found  that  in 
terms  of  patient  survival  and  tumour  response,  both 
modalities  showed  similar  efficacy  in  the  treatment  of 
HCC. The overall survival rates at six months, one, two, 
three, and four years were 69%, 38%, 22%, 14%, and 
10%, respectively, in the I 131 lipiodol group and 66%, 
42%,  22%,  3%,  and  0%,  respectively,  in  the  chemo 
embolisation  group.  Tolerance  of  I 131  lipiodol  was 
significantly better with three severe side effects noted in 
the  I 131  lipiodol  group  and  29  in  the 
chemoembolisation group (p <0.001).  
There  is  also  a  role  for  I 131  lipiodol  therapy  in 
some patients with portal vein thrombosis where TACE 
is  generally  contraindicated.  I 131  lipiodol  does  not 
modify  arterial  flow  and  appears  feasible  in  some 
patients  with  portal  vein  thrombosis.  In  a  French 
randomised  study  [15],  14  HCC  patients  were 
randomised  to  I 131  lipiodol  therapy  and  11  HCC 
patients to medical support consisting of tamoxifen (five 
patients),  intravenous  5  fluorouracil  (one  patient),  and 
non steroidal anti inflammatory drugs or corticosteroids 
(five patients). The survival rates at three, six, and nine 
months were 71%, 48%, and 7%, respectively, for the 
treatment group and 10%, 0%, and 0%, respectively, for 
the control group. Overall, the tolerance was excellent in 
the treated group. 
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In general, intra arterial I 131 lipiodol treatment of 
HCC is well tolerated [12]. Some reported side effects 
for  this  treatment  include  fever,  mild  abdominal  pain, 
nausea,  elevation  of  transaminases,  and  radiation 
hepatitis [14]. Most of the side effects are, however, mild 
and tend to resolve with minimal or no intervention. Pre 
treatment  with  Lugol’s  iodine  will  result  in  adequate 
thyroid uptake blockage. There may be a possible role 
for  the  use  of  both  radionuclide  therapy  and  TACE 
together for palliative treatment of HCCs as there may be 
a  synergistic  effect.  Data  on  this  form  of  combination 
therapy  are,  however,  lacking  and  further  studies  are 
awaited. 
Y 90 MICROSPHERES 
Y 90 is a stronger pure β emitter than I 131. It emits 
β rays with an average energy of 935 keV and has a half 
life of 64 hours and a maximum penetration or β range of 
11 mm. Y 90 does not emit γ rays and is not optimal for 
imaging purposes. Y 90 can be embedded in insoluble, 
non biodegradable  glass  or  resin  microspheres  (mean 
diameters of 25  m to 35  m). Administration of the Y 
90 microspheres via the intra hepatic, intra arterial route 
will  result  in  the  deposition  of  the  glass  or  resin 
microspheres in the tumour terminal vasculature. HCCs 
have a relatively greater arteriolar density compared with 
the normal liver and are predominantly supplied by the 
hepatic artery rather than the portal venous system. This 
will result in a three fold or greater radiation dose in the 
tumour nodules relative to the normal liver [18]. Y 90 
microspheres can deliver a higher radiation dose to the 
liver  tumour  compared  with  I 131  lipiodol.  Y 90 
microspheres can be safely administered via intra arterial 
injection to patients with HCC and underlying cirrhosis 
at a dose of 100 Gy to the liver [19]. With this technique, 
an  initial  angiography  scout  dose  with  Tc 99m 
macroaggregated  albumin  or  other  similar  agent  is 
required to document the presence of significant porto 
systemic shunting in the presence of portal hypertension. 
Y 90 microspheres are generally not given when the lung 
uptake  is  >15%,  which  indicates  significant  porto 
systemic  shunting.  Extrahepatic  shunting  is  the  main 
limitation to this form of therapy. 
This form of therapy appears to be safe. Andrews et 
al conducted a phase I dose escalation study using intra 
arterial  Y 90  microspheres  with  estimated  whole  liver 
nominal absorbed doses ranging from 50 Gy to 150 Gy 
[20]. They did not find any haematologic, hepatic, and 
pulmonary toxicity during a mean follow up period of up 
to 53 months. Reversible gastritis and duodenitis  were 
encountered in four patients. Other reported side effects 
associated  with  this  form  of  treatment  included  fever, 
elevation  of  liver  enzymes  and  bilirubin,  and 
gastrointestinal  toxicities,  such  as,  ulcers,  ileus,  and 
nausea. Most of the side effects did not require treatment 
and resolved spontaneously. There was one reported case 
of  death  resulting  from  radiation  pneumonitis.  This 
patient, however, had 39% pulmonary shunting, and it is 
questionable  whether  the  patient  should  have  been 
eligible for treatment.  
Several  studies  have  reported  the  use  of  Y   90 
microspheres  for  the  treatment  of  HCC  [21 22].  The 
activity of Y 90 microspheres administered ranged from 
1554  MBq  to  5,000  MBq  for  initial  treatment  with 
cumulative activity of up to 13,000 MBq from repeated 
treatments [23,24]. Using the intra arterial approach of 
administering  the  Y 90  microspheres,  it  is  possible  to 
deliver radiation doses of up to 748 Gy to the tumour at a 
single treatment session and cumulative tumour radiation 
doses of up to 1,580 Gy [21]. An objective response rate 
of  80%,  in  terms  of  reduction  of  serum  α fetoprotein 
levels,  has  been  reported  [21].  Other  authors  have 
reported an objective response rate of 20% in terms of 
radiological regression of tumour [22]. Median survival 
of 9.4 months to 54 weeks has been achieved with the 
use of Y 90 microspheres [21 25]. Interestingly, Lau et 
al reported four patients whose tumours were converted 
into resectable ones and these underwent resection [21]. 
The disadvantage of this treatment is the high cost and 
the need for two hepatic angiograms. 
RE 188 LIPIODOL 
Re 188 has recently been used to treat HCCs. It has 
a physical half life of 16.9 hours and emits β rays with 
an average energy of 795 KeV and γ rays of 155 KeV in 
15%  abundance.  Gamma  camera  imaging  for 
biodistribution studies is possible with this radionuclide. 
Re 188 was eluted from a W 188/Re 188 generator that 
has a long and a useful shelf life of several months and, 
therefore,  provides  a  constant  yield  of  carrier free  Re 
188 on a routine basis. This could potentially be cost 
saving when compared to the use of other radionuclides 
and would be particularly useful in the context of treating 
HCC in developing countries, where incidence is among 
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the highest in the world. The concentrated elute from the 
tungsten rhenium generator was heated with 4 hexadecyl 
1 2, 9, 9 tetramethyl 4, 7 diaza 1, 10 decanethiol (HDD) 
in a water bath for one hour to produce a rhenium HDD 
complex. The HDD lyophilised kits were obtained from 
Seoul  National  University  Hospital  in  Korea.  Lipiodol 
was added and centrifuged to extract the Re HDD into 
the lipiodol. This method of preparation was previously 
described  by  Jeong  et  al  [26]  and  Lee  et  al  [27].  An 
International  Atomic  Energy  Agency sponsored  multi 
centre pilot study using intra arterial Re 188 lipiodol for 
the  treatment  of  inoperable  HCC  showed  safety  and 
efficacy  of  this  radioconjugate  [28].  Sixteen  patients 
were treated with Re 188 lipiodol in this study. A “scout 
dose” was given, from which the maximal tolerated dose 
(MTD)  was  determined  using  a  specially  designed 
spreadsheet.  The  MTD  is  defined  as  the  amount  of 
radioactivity calculated to deliver no more than 12 Gy to 
the  lungs,  30  Gy  to  the  liver,  or  1.5  Gy  to  the  bone 
marrow. These doses have been found to be safe. This 
method of treatment appears to be safe and well tolerated 
at  doses  up  to  7,400  MBq  Re 188  lipiodol.  The  side 
effects  were  minimal  and  included  slight  elevation  of 
liver  enzymes  (alanine  transaminase  and  aspartate 
transaminase)  at  24  hours,  mild  nausea,  mild 
hypochondrial pain, fever, and vomitting. The efficacy of 
this  new  radionuclide  for  the  treatment  of  HCC  was 
confirmed in a larger, multi centre phase 2 study [29]. 
Similar results were also reported by Lambert et al [30]. 
Table  1  below  gives  a  summary  of  the  various 
radionuclides  used  in  the  treatment  of  HCC.  Figure  1 
shows a CT scan and Re 188 treatment scan. Figure 2 
shows  CT  scans  of  liver  tumour;  Figure  3  shows  the 
angiogram  image;  and  Figure  4  shows  the  Yttrium 90 
treatment dose image using the bremsstrahlung radiation.  
RADIO LABELLED MONOCLONAL ANTIBODIES TO TREAT 
HCC 
There  are  a  few  monoclonal  antibodies  against 
antigens, such as, CEA, ferritin, and α fetoprotein, which 
have some degree of specificity for HCC. Both anti CEA 
and antiferritin antibodies have been labelled with I 131 
and  Y 90  and  are  administered  parenterally  for  the 
treatment of HCC. The results have been encouraging, 
although  experience  with  this  method  of  treatment  is 
limited to only a few centres. The efficacy of this form of 
treatment may be limited by the fact that the tumour cells 
are generally heterogeneous and not all the cells express 
the  same  antigen.  There  is  also  a  possibility  of 
developing human antimouse antibodies with the use of 
antibodies of murine origin. This will prevent subsequent 
treatment. 
ADJUVANT TREATMENT WITH I 131 LIPIODOL AFTER 
CURATIVE RESECTION OF HCC  
Resection  of  HCC  is  potentially  curative,  but  the 
recurrence rate is 100% at 5 years. It is hypothesised that 
the high recurrence rate is due to microscopic metastatic 
disease or metachronous multicentric tumour present in 
the remnant liver not detected before and at the time of 
surgery by the usual imaging methods. Various systemic 
and locoregional chemotherapy agents have been tried to 
reduce the rate of recurrence. The overall results show 
marginal or no significant improvement in disease free 
survival. The efficacy of these forms of therapy is also 
limited by the toxicity of the chemotherapeutic agents. 
The  presence  of  underlying  cirrhosis  further  limits  the 
ability of the liver remnant to tolerate these agents. In 
adjuvant  therapy,  there  appears  to  be  a  role  for 
radionuclide  therapy  in  improving  disease free  and 
overall  survival  following  curative  resection  of  HCC. 
Lau et al randomised 21 patients to receive one 1,850 
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MBq dose of intra arterial I 131 lipiodol and 22 patients 
to no adjuvant treatment following curative resection of 
HCC  [31].  The  median  disease free  survival  in  the 
treatment and control groups was 57.2 months and 13.6 
months, respectively. The three year overall survival for 
the treatment and control groups was 86.4% and 46.3%, 
respectively.  In  a  more  recent  study,  Partensky  et  al 
reported  a  median  time  to  detected  recurrence  of  28 
months  (range  12  to  62  months)  for  28  patients  [32]. 
Each patient was treated with one 1,110 MBq dose of 
intra arterial I 131 lipiodol following curative resection 
of HCC. The overall survival rates  were 86% at three 
years and 65% at five years. In our preliminary study, the 
six month disease free survival rate was 100% and the 
12 month  disease free  and  overall  survival  rates  were 
72%  and  85%,  respectively,  for  15  patients  who  had 
received  I 131  lipiodol  adjuvant  therapy  following 
curative resection of HCC [33]. This form of adjuvant 
therapy appears to be safe with no clinically adverse side 
effects reported. Adjuvant radionuclide therapy may also 
have  a  possible  role  in  reducing  the  rate  of  tumour 
recurrence  after  minimally  invasive  percutaneous 
treatment of small HCC, such as, PEI and RFA.  
OTHER METHODS 
Some  work  has  been  done  using  P 32  glass 
micospheres intrarterially, and the results are similar to 
TACE  alone  [34].  Re 186  and  Re 188  glass 
microspheres have been effective in animal models, but 
clinical data are lacking [35]. Ho 166 microspheres and 
chitosan complex are used in Korea for the treatment of 
inoperable HCC [36]. 
CONCLUSION  
Treatment  of  HCC  involves  multi disciplinary 
collaboration. In cases of multi segmental or large HCCs, 
palliative treatment using radionuclide therapy is a viable 
alternative to TACE. The survival rates are similar for 
both modalities, but radionuclide therapy appears to be 
better  tolerated  with  less  severe  side  effects.  In  rare 
instances,  unresectable  tumours  may  be  converted  to 
respectable  tumours  after  radionuclide  therapy. 
Radionuclide  treatment  in  a  curative  intent  may  be 
possible for small HCCs in instances where surgery or 
percutaneous  treatment  is  not  possible  due  to  tumour 
location or severe concurrent medical illnesses. Adjuvant 
radionuclide therapy appears to have a promising role in 
reducing the rate of tumour recurrence after surgery for 
resectable  HCCs  and  after  percutaneous  treatment  of 
small HCCs. 
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Table 1  A summary of the various radionuclides used in the treatment of HCC. 
Radionuclides  Half life (T1/2) 
(hrs) 
Mean β energy  
(MeV) 
γ energy  
(keV) 
Yttrium 90 (microspheres)  64  0.94     
Iodine 131 (lipiodol)  144  0.19  364  
Rhenium 188  17  0.79  155  
Holmium 166 (chitosan complex)  27  0.67  138  
Technetium 99m (macroaggregated 
albumin) 
6     140  
 